Your browser doesn't support javascript.
loading
Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients.
Rico-Caballero, Verónica; Fernández, Mariana; Hurtado, Juan C; Marcos, M Angeles; Cardozo, Celia; Albiach, Laia; Agüero, Daiana; Ambrosioni, Juan; Bodro, Marta; Chumbita, Mariana; De la Mora, Lorena; Garcia-Pouton, Nicole; Gonzalez-Cordón, Ana; Dueñas, Gerard; Hernandez-Meneses, Marta; Inciarte, Alexy; Laguno, Montse; Leal, Lorna; Macaya, Irene; Martínez, Miguel J; Cuesta, Genoveva; Meira, Fernanda; Morata, Laura; Puerta-Alcalde, Pedro; Rojas, John; Torres, Berta; Castro, Pedro; Muñoz, Jose; Mensa, Josep; Martínez, José Antonio; Sanjuan, Gemma; Vila, Jordi; García, Felipe; Garcia-Vidal, Carolina; Soriano, Alex.
Afiliación
  • Rico-Caballero V; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Fernández M; Department of Microbiology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Hurtado JC; Institute for Global Health (ISGlobal), University of Barcelona, Barcelona, Spain.
  • Marcos MA; Department of Microbiology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Cardozo C; Institute for Global Health (ISGlobal), University of Barcelona, Barcelona, Spain.
  • Albiach L; Department of Microbiology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Agüero D; Institute for Global Health (ISGlobal), University of Barcelona, Barcelona, Spain.
  • Ambrosioni J; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Bodro M; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Chumbita M; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • De la Mora L; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Garcia-Pouton N; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Gonzalez-Cordón A; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Dueñas G; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Hernandez-Meneses M; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Inciarte A; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Laguno M; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Leal L; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Macaya I; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Martínez MJ; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Cuesta G; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Meira F; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Morata L; Department of Microbiology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Puerta-Alcalde P; Institute for Global Health (ISGlobal), University of Barcelona, Barcelona, Spain.
  • Rojas J; Department of Microbiology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Torres B; Institute for Global Health (ISGlobal), University of Barcelona, Barcelona, Spain.
  • Castro P; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Muñoz J; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Mensa J; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Martínez JA; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Sanjuan G; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Vila J; Medical Intensive Care Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • García F; Centre for Research in International Health (CRESIB), Hospital Clinic, University of Barcelona, ISGLOBAL, Barcelona, Spain.
  • Garcia-Vidal C; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
  • Soriano A; Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/ Villarroel 170, 08036, Barcelona, Spain.
Infection ; 50(5): 1321-1328, 2022 Oct.
Article en En | MEDLINE | ID: mdl-35562568
PURPOSE: Assess the impact of viral load estimated by cycle threshold (Ct) of reverse transcription real time-polymerase chain reaction (rRT-PCR) and the days from symptoms onset on mortality in hospitalized patients with COVID19. METHODS: Retrospective observational study of 782 patients with a positive rRT-PCR from a nasopharyngeal swab was performed within the first 24 h from admission. Demographic data, clinical manifestations and laboratory parameters were collected. Uni- and multivariate analyses were performed to identify factors associated with mortality at 60 days. RESULTS: Ct was divided into three groups and the mortality rate decreased from 27.3 to 20.7% and 9.8% for Ct values of ≤ 20, 21-25 and > 25, respectively (P = 0.0001). The multivariate analysis identified as predictors of mortality, a Ct value < 20 (OR 3.13, CI 95% 1.38-7.10), between 21-25 (OR 2.47, CI 95% 1.32-4.64) with respect to a Ct value > 25. Days from symptoms onset is a variable associated with mortality as well (DSOA) ≤ 6 (OR 1.86, CI 95% 1.00-3.46), among other factors. Patients requiring hospital admission within 6 DSOA with a Ct value ≤ 25 had the highest mortality rate (28%). CONCLUSIONS: The inclusion of Ct values and DSOA in the characterization of study populations could be a useful tool to evaluate the efficacy of antivirals.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Idioma: En Revista: Infection Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Idioma: En Revista: Infection Año: 2022 Tipo del documento: Article